Avenue Therapeutics
menu
  • About
    • Management Team
    • Board of Directors
  • Pipeline
    • BAER-101
    • IV Tramadol
    • AJ201
  • Publications
  • Investors
    • News & Events
      • Overview
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Info
      • Overview
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Overview
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
      • Analyst Coverage
    • Stock Data
      • Quote
      • Charts
      • Historical Data
    • SEC Filings
      • Overview
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Overview
      • Board of Directors
      • Board Committees
      • Governance Documents
  • Events
  • Contact Us
    • Careers
      • Email Alerts

Press Releases

Investors

Investors

  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Analyst Coverage
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Feb 15, 2022

Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol

Feb 15, 2022

Avenue Therapeutics Stock Trading Halted Today

Dec 15, 2021

Avenue Therapeutics Announces Closing of Public Offering of Common Stock

Dec 12, 2021

Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock

Nov 29, 2021

Avenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol NDA Tentatively Scheduled for February 15, 2022

Nov 17, 2021

Avenue Therapeutics Announces Exercise and Closing of Underwriter’s Over-Allotment Option

Nov 12, 2021

Avenue Therapeutics Announces Closing of Public Offering of Common Stock

Nov 09, 2021

Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock

Oct 25, 2021

Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs

Jun 14, 2021

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • Privacy
  • Disclaimer
  • Contact Us


twitter icon linked-in icon
Website Design, Maintenance and Hosting by Tidal Media Group
Copyright ©2025 Avenue Therapeutics.

logo